AMENDMENTS TO THE CLAIMS

1. – 14. (Canceled)

15. (Previously Presented) An isolated protein consisting of the amino acid sequence set forth in SEQ ID NO: 4.

16. (Previously Presented) A pharmaceutical composition, which comprises the protein of Claim 15 and one or more pharmaceutically acceptable additives.

17. (Previously Presented) The pharmaceutical composition according to Claim 16, wherein said one or more pharmaceutically acceptable additives is selected from the group consisting of a pH regulator, a buffer, a stabilizer, and a preservative.

18. (Previously Presented) The pharmaceutical composition according to Claim 16, wherein said protein is in an amount of 1 pg to 1 g.

19. (Previously Presented) The pharmaceutical composition according to Claim 16, wherein said composition is in a preparation form selected from the group consisting of an injection, an inhalant, a tablet, a granule, a powder, a capsule, and a suppository.

20. – 30. (Canceled)

31. (Currently Amended) An isolated protein, which has a binding activity to an insulin receptor-related receptor and the following characteristics:

(a) ~~it comprises~~ the protein comprises the amino acid sequence of SEQ ID NO: 4

(b) ~~it has~~ the protein has a molecular weight of about 6135, 6206, 6250 or 6321 measured by mass spectrometry using the Fourier transformation ion cyclotron method.

32. (Currently Amended) ~~A isolated~~ An isolated protein, which ~~has a binding activity~~ binds to an insulin receptor-related receptor, wherein the protein comprises an amino acid sequence selected from the group consisting of:

- an amino acid sequence of SEQ ID NO: 4,
- an amino acid sequence of SEQ ID NO: 3 ~~SEQ ID NO: 4 having an addition of an aspartic acid residue to the N-terminus and a deletion of a C-terminal aspartic acid residue~~,
- an amino acid sequence of SEQ ID NO: 5 ~~SEQ ID NO: 4 having an addition of an aspartic acid residue to the N-terminus~~,
- an amino acid sequence of SEQ ID NO: 6 ~~SEQ ID NO: 4 having an addition of an aspartic acid residue to the N-terminus and an addition of an alanine residue to the C-terminus~~, and
- an amino acid sequence of SEQ ID NO: 7 ~~SEQ ID NO: 4 having an addition of an alanine residue to the C-terminus~~.

33. (Previously Presented) A pharmaceutical composition, which comprises the protein of Claim 32 and one or more pharmaceutically acceptable additives.

34. (Previously Presented) The pharmaceutical composition according to Claim 33, wherein said one or more pharmaceutically acceptable additives is selected from the group consisting of a pH regulator, a buffer, a stabilizer, and a preservative.

35. (Previously Presented) The pharmaceutical composition according to Claim 33, wherein said protein is in an amount of 1 pg to 1 g.

36. (Previously Presented) The pharmaceutical composition according to Claim 33, wherein said composition is in a preparation form selected from the group consisting of an injection, an inhalant, a tablet, a granule, a powder, a capsule, and a suppository.

37. – 47. (Canceled)

SUPPORT FOR THE AMENDMENTS

Claims 1-14 were canceled previously.

Claims 20-30 and 37-47 are canceled herein.

Claims 31 and 32 have been amended.

The amendment of Claims 31 and 32 is supported by original Claims 1 and 2, page 7, lines 25-26, Example 4 (page 30, line 14 to page 32, line 21), and the Sequence Listing as originally filed.

No new matter has been entered by the present amendment.